Elevance Health (NYSE:ELV - Get Free Report) is set to post its quarterly earnings results before the market opens on Wednesday, July 17th. Analysts expect Elevance Health to post earnings of $10.00 per share for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.
Elevance Health (NYSE:ELV - Get Free Report) last issued its earnings results on Thursday, April 18th. The company reported $10.64 earnings per share for the quarter, topping analysts' consensus estimates of $10.54 by $0.10. Elevance Health had a return on equity of 20.62% and a net margin of 3.64%. The business had revenue of $42.27 billion during the quarter, compared to analyst estimates of $42.49 billion. During the same quarter in the previous year, the firm earned $9.46 EPS. Elevance Health's revenue was up .9% on a year-over-year basis. On average, analysts expect Elevance Health to post $37 EPS for the current fiscal year and $42 EPS for the next fiscal year.
Elevance Health Stock Performance
NYSE:ELV traded up $5.35 during mid-day trading on Wednesday, reaching $534.59. The company's stock had a trading volume of 629,762 shares, compared to its average volume of 1,013,092. Elevance Health has a 12-month low of $412.00 and a 12-month high of $550.34. The firm's fifty day moving average price is $534.14 and its two-hundred day moving average price is $512.28. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.54. The stock has a market cap of $124.25 billion, a P/E ratio of 20.20, a PEG ratio of 1.16 and a beta of 0.84.
Elevance Health Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 25th. Shareholders of record on Monday, June 10th were given a $1.63 dividend. This represents a $6.52 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date of this dividend was Monday, June 10th. Elevance Health's dividend payout ratio (DPR) is 24.64%.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on ELV. StockNews.com lowered Elevance Health from a "strong-buy" rating to a "buy" rating in a research report on Thursday, June 6th. Bank of America boosted their price target on Elevance Health from $621.00 to $646.00 and gave the company a "buy" rating in a research note on Tuesday, June 4th. Truist Financial restated a "buy" rating and set a $600.00 price target (up from $580.00) on shares of Elevance Health in a research note on Friday, April 19th. Barclays boosted their price target on Elevance Health from $584.00 to $621.00 and gave the company an "overweight" rating in a research note on Friday, April 19th. Finally, Wells Fargo & Company boosted their price target on Elevance Health from $557.00 to $600.00 and gave the company an "overweight" rating in a research note on Friday, April 19th. One investment analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Elevance Health presently has an average rating of "Buy" and a consensus price target of $611.36.
Get Our Latest Analysis on Elevance Health
Insider Buying and Selling
In related news, EVP Felicia F. Norwood sold 14,111 shares of the business's stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $533.74, for a total value of $7,531,605.14. Following the transaction, the executive vice president now directly owns 31,460 shares of the company's stock, valued at approximately $16,791,460.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.29% of the stock is owned by insiders.
Elevance Health Company Profile
(
Get Free Report)
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Featured Articles
Before you consider Elevance Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.
While Elevance Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
